Two Omega directors resign; Jeffrey Varsalone appointed to board

Omega Therapeutics, Inc.

Ravi Mehrotra and Robert Rosiello resigned from the board effective January 22, 2025.
Board appointed Jeffrey Varsalone as Class I director effective January 24, 2025; monthly cash fee of $30,000.
Richard Kender moved from Class III to Class II director to rebalance board classes.
Board now consists of two directors per class (I, II, III).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey T. Varsalone

Class I Director

Omega Therapeutics, Inc.

Effective: 2025-01-24
Filed: January 28, 2025, 6:59 PM ET

On January 24, 2025, the Board appointed Jeffrey T. Varsalone as a Class I director of the Company, effective immediately.

Departed

Robert L. Rosiello

Class I Director

Omega Therapeutics, Inc.

Effective: 2025-01-22
Filed: January 28, 2025, 6:59 PM ET

On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.

Departed

Ravi Mehrotra

Class I Director

Omega Therapeutics, Inc.

Effective: 2025-01-22
Filed: January 28, 2025, 6:59 PM ET

On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey T. Varsalone was appointed as Class I Director at Omega Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On January 24, 2025, the Board appointed Jeffrey T. Varsalone as a Class I director of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert L. Rosiello resigned as Class I Director at Omega Therapeutics, Inc..

Action: resigned
Role: Class I Director

Exact text from the filing

On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ravi Mehrotra resigned as Class I Director at Omega Therapeutics, Inc..

Action: resigned
Role: Class I Director

Exact text from the filing

On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-014403

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.